Puchuang Medical Launches China's First Independently Developed Intravascular Lithotripsy System for Coronary Artery Calcification

Intravascular Shockwave Lithotripsy is a new technology for treating vascular calcification lesions. Extracorporeal shockwave lithotripsy has been safely used in the treatment of kidney stones for over 30 years and is gradually being explored for application in the treatment of vascular calcification lesions.

In March this year, the coronary intravascular shock wave treatment system independently developed by Spectrumedics Medical Technology (Shanghai) Co., Ltd. was officially approved for marketing by the National Medical Products Administration (NMPA).The system is by SONICO-CX^®Disposable Coronary Intravascular Shockwave Catheter (NMPA Approval No. 20243010464) and Intravascular Shockwave Treatment Device (NMPA Approval No. 20243010505). The treatment device provides pulsed driving electrical energy to the shockwave catheter, releasing shockwaves circumferentially at 360° and intermittently. The acoustic energy directly targets and fractures calcified plaques within the intima and media, restoring vascular compliance while avoiding damage to the vascular endothelium.

This isCurrently, the only domestically produced and self-developed coronary intravascular shock wave treatment product in China to have received an authorized invention patent, successfully breaking through the technical bottlenecks of similar foreign technologies.

Friday, October 25th, 19:30, VCBeat New Product Review Session 104, invitedFounder of SpectrumedicsPeng Huiqun,Gao Zhishuang, Director of Marketing Department, SpectrumedicsYu Fei, Head of Clinical Medicine Department at SpectrumedicsThree GuestsBrings the introduction of Spectrumedics products.

SONICO-CX^®The disposable coronary intravascular shock wave treatment system consists of a disposable coronary intravascular shock wave catheter, an intravascular shock wave treatment device, and a foot pedal switch.

Smaller outer diameter:Electrode single-layer longitudinal arrangement enhances the ability to pass through narrow blood vessels.

More Uniform Release Range:Electrode ring-end design, 360° circumferential release of shock waves

Higher Pulse Count:Single catheter with 120 pulses effectively resolves intraoperative "pulse anxiety"

Better Operating Habits:Efficient and Safe Surgical Operation Habits, Freeing the Surgeon's Hands

Longer working hours:Power supply without charging, continuous uninterrupted operation

Scan the QR code on the poster to add the assistant and schedule a live broadcast.

Peng Huiqun

Spectrumedics | Founder

Ph.D. in Biology from Nanyang Technological University, Singapore, affiliated with the research group of Nobel laureate Professor Sydney Brenner. Industry advisor to the Biomedical Engineering Committee at the National University of Singapore. Has led the development of multiple Class III innovative devices, including transcatheter mitral/tricuspid valve replacement and repair, next-generation drug-coated balloons, etc. With nearly 10 years of experience in device R&D, patent strategy formulation, international multicenter clinical studies, and team building. Has also collaborated extensively with internationally renowned medical experts in cardiac surgery, cardiology, vascular surgery, and other fields.

Gao Zhishuang

Spectrumedics | Director of Marketing

19 years of immersive experience in the medical device industry, having served in segments such as cardiac intervention, oncology intervention, IVD, and orthopedics.Highly familiar with the overall operational processes of the medical device industry, adhering to the principle of serving business development and avoiding operational risks as the starting point, fostering a management philosophy for sustainable organizational growth.

Yu Fei

Spectrumedics | Head of Clinical Medicine Department

Master of Clinical Medicine, Attending Physician in Cardiology, with over 10 years of experience in clinical cardiology and innovative medical devices. Proficient in clinical diagnosis and treatment techniques for cardiovascular diseases, and has published multiple SCI papers. Participated in the research and development and clinical application studies of various innovative medical devices.

Spectrumedics Medical Technology (Shanghai) Co., Ltd. was founded in 2019 by returned overseas Chinese who have深耕ed in the cardiovascular device field for many years. Headquartered in Shanghai, it is a platform-type innovative medical technology enterprise focusing on cardiac and泛血管active minimally invasive interventional technologies. The company's core product, the "Intravascular Shock Wave Catheter System," is the only domestically produced自主研发product to receive an invention patent authorization and successfully突破similar foreign technical bottlenecks. This technology focuses on overcoming various challenges of vascular calcification and is first applied in treating stenotic calcified lesions in coronary arteries and peripheral lower limb arteries.

In the field of intravascular shockwave technology, the company has obtained 6 Chinese invention patents, 13 utility model patents, 3 PCT international patent applications, and 1 Singaporean invention patent. It was also recognized as a National High-tech Enterprise in 2023. The company's first Class III medical device product in China for treating vascular calcification lesions — the coronary intravascular liquid-electric shockwave system — has been approved for marketing, with 5 additional new products currently under development.

The company has two research and development centers in China and overseas. The professional backgrounds of the core team members cover multiple disciplines such as electrical, mechanical, acoustics, bioengineering, and biomaterials, with in-depth cooperation with well-known medical experts at home and abroad. The R&D center and production base in Shanghai are equipped with a 500-square-meter R&D laboratory, a 3,000-square-meter GMP facility, and a Class 10,000 cleanroom, possessing complete R&D, testing, and production capabilities.

The company has successfully completed a RMB 100 million Series A+ round of financing, with investors including well-known medical investment institutions such as Legend Capital, BAI Capital, and Yang Capital.

"VCBeat New Product Review" is a live broadcast column that supports the launch of innovative products by medical companies. The aim of the column is to support every milestone release of medical innovation products. If your company has plans to launch innovative medical products or major milestones and would like to participate in the VCBeat New Product Review, please contact the assistant for consultation.

Scan the QR code below to contact the assistant for live broadcast reservation (if already added, please ask the assistant directly).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant to send a live broadcast screenshot, participate in the lucky draw for a chance to win 【15-day trial membership of VCBeat's VBInsight】.